| [1] |
Lam MP, Ping P, Murphy E. Proteomics research in cardiovascular medicine and biomarker discovery[J]. J Am Coll Cardiol, 2016, 68(25): 2819-2830.
doi: S0735-1097(16)36779-1
pmid: 28007144
|
| [2] |
Castiglione V, Aimo A, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure[J]. Heart Fail Rev, 2022, 27(2): 625-643.
doi: 10.1007/s10741-021-10105-w
URL
|
| [3] |
Kullo IJ, Cooper LT. Early identification of cardiovascular risk using genomics and proteomics[J]. Nat Rev Cardiol, 2010, 7(6): 309-317.
doi: 10.1038/nrcardio.2010.53
pmid: 20440292
|
| [4] |
de Boer RA, De Keulenaer G, Bauersachs J, et al. Towards better definition, quantification and treatment of fibrosis in heart failure[J]. Eur Heart J, 2019, 21(3): 272-285.
|
| [5] |
Atienza F, Martins RP, Jalife J. Translational research in atrial fibrillation[J]. Circ Arrhythm Electrophysiol, 2012, 5(6): 1207-1215.
doi: 10.1161/CIRCEP.111.970335
pmid: 23022707
|
| [6] |
Nattel S, Heijman J, Zhou L, et al. Molecular basis of atrial fibrillation pathophysiology and therapy[J]. Circ Res, 2020, 127(1): 51-72.
doi: 10.1161/CIRCRESAHA.120.316363
URL
|
| [7] |
Alonso R, Mata P, Muñiz O, et al. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia[J]. Atherosclerosis, 2016, 254: 249-253.
doi: S0021-9150(16)31306-5
pmid: 27594539
|
| [8] |
Laugsand LE, Åsvold BO, Vatten LJ, et al. Circulating PCSK9 and risk of myocardial infarction[J]. JACC Basic Transl Sci, 2016, 1(7): 568-575.
doi: 10.1016/j.jacbts.2016.06.007
pmid: 30167541
|
| [9] |
Shapiro MD, Tavori H, Fazio S. PCSK9: from basic science discoveries to clinical trials[J]. Circ Res, 2018, 122(10): 1420-1438.
doi: 10.1161/CIRCRESAHA.118.311227
pmid: 29748367
|
| [10] |
Shapiro MD, Fazio S, Tavori H. Targeting PCSK9 for therapeutic gains[J]. Curr Atheroscler Rep, 2015, 17(4): 499.
|
| [11] |
Fitzgerald K, Simon A, White S, et al. A subcutaneously administered investigational RNAi therapeutic (ALN-PCSsc), targeting PCSK9 for the treatment of hypercholesterolemia: initial phase Ⅰ study results[C/OL]. http://www.pcsk9forum.org/wp-content/uploads/aln_pcssc_phase_ I_ data.pdf.
|
| [12] |
Landlinger C, Pouwer MG, Juno C, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden[J]. Eur Heart J, 2017, 38(32): 2499-2507.
doi: 10.1093/eurheartj/ehx260
pmid: 28637178
|
| [13] |
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med, 2017, 376(18): 1713-1722.
doi: 10.1056/NEJMoa1615664
URL
|
| [14] |
Poller W, Dimmeler S, Heymans S, et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives[J]. Eur Heart J, 2018, 39(29): 2704-2716.
doi: 10.1093/eurheartj/ehx165
pmid: 28430919
|
| [15] |
Ravi S, Mitchell T, Kramer P, et al. Mitochondria in monocytes and macrophages-implications for translational and basic research[J]. Int J Biochem Cell Biol, 2014, 53: 202-207.
doi: 10.1016/j.biocel.2014.05.019
pmid: 24863362
|
| [16] |
Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection[J]. Sci Signal, 2009, 2(100): ra81.
|
